Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.8%

100 terminated/withdrawn out of 1020 trials

Success Rate

84.3%

-2.2% vs industry average

Late-Stage Pipeline

7%

73 trials in Phase 3/4

Results Transparency

49%

262 of 537 completed trials have results

Key Signals

214 recruiting262 with results80 terminated20 withdrawn

Enrollment Performance

Analytics

N/A
411(48.4%)
Phase 2
188(22.1%)
Phase 1
158(18.6%)
Phase 3
38(4.5%)
Phase 4
35(4.1%)
Early Phase 1
20(2.4%)
850Total
N/A(411)
Phase 2(188)
Phase 1(158)
Phase 3(38)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1020)

Showing 20 of 1020 trials
NCT03386539Phase 3Completed

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Role: collaborator

NCT06866262Phase 1Recruiting

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Role: collaborator

NCT07377526Phase 1Suspended

TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Role: collaborator

NCT06411691Phase 1Recruiting

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Role: collaborator

NCT05663710Phase 1Recruiting

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Role: collaborator

NCT05823766Active Not Recruiting

Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)

Role: collaborator

NCT07047807Not ApplicableRecruiting

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT06871410Phase 1Recruiting

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT04416412Completed

ICG Fluorescence Imaging in Open Fracture Trauma Patients

Role: collaborator

NCT03258658Phase 1Recruiting

Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures

Role: collaborator

NCT07665294Phase 4Not Yet Recruiting

Combination CurQD and Vedolizumab in Ulcerative Colitis

Role: collaborator

NCT05242965Phase 2Recruiting

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Role: collaborator

NCT03582176Phase 3Completed

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

Role: collaborator

NCT06217081Terminated

3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions

Role: collaborator

NCT05684692Phase 2Recruiting

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Role: collaborator

NCT07166120Not ApplicableRecruiting

Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients

Role: collaborator

NCT05570851Not ApplicableCompleted

Alcohol Cessation Among Head and Neck Cancer Survivors

Role: collaborator

NCT06458036Phase 2Recruiting

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Role: collaborator

NCT06081543Not ApplicableRecruiting

Ketogenic Diet vs Mixed Diet in Patients With Heart Failure

Role: collaborator

NCT07721259Phase 2Not Yet Recruiting

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Role: collaborator